« Return to News | Drug Sponsors

Biogen Idec acquires Stromedix for $75 million

Wednesday, February 15, 2012 03:01 PM

Biogen Idec has acquired Stromedix, a privately held biotechnology company focused on therapies for fibrosis and organ failure, for $75 million cash.

Biogen Idec will make additional contingent value payments of up to $487.5 million based on the achievement of certain development and approval milestones across multiple indications.

Stromedix's lead candidate, STX-100, is a novel humanized monoclonal antibody that selectively disrupts the TGF-beta pathway, which plays a central role in fibrotic disease. It has demonstrated an attractive safety and tolerability profile in a phase I trial, and is entering a phase II trial in patients with idiopathic pulmonary fibrosis (IPF).

"By joining forces, we expect to accelerate the development of STX-100 and other promising early-stage drug candidates,” said Michael Gilman, Ph.D., founder and CEO of Stromedix, who previously led Biogen Idec's research organization from 2000 to 2005.

"We believe STX-100 has the potential to be a best-in-class therapy and it is an excellent strategic fit with our focus on highly differentiated programs with the potential to make a real difference for patients," said Douglas E. Williams, executive vice president of R&D, Biogen Idec. “We are pleased to welcome Mike and his team back to Biogen Idec to drive STX-100's continued development.”

The transaction is subject to customary closing conditions.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.